Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 23, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - July 23, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

7/16/17 - AVEO Oncology Announces Positive CHMP Opinion for Tivozanib as a Treatment of Advanced Renal Cell Carcinoma
By a News Reporter-Staff News Editor at Marketing Business Weekly AVEO Oncology announced that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has recommended FOTIVDA? for approval as a treatment for patients with advanced renal cell carcinoma. If approved by the EC, marketing autho
7/16/17 - Illumina Announces FDA-approved Next-Generation Sequencing Cancer Companion Diagnostic Test Kit
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA Illumina, Inc. announced its Extended RAS Panel, an FDA- approved next-generation sequencing kit that meets the newly published guidelines for evaluation of colorectal cancer from the American Society for Clinical Pathology, the College of American Pathologists, the Associatio
7/16/17 - Mississippi ready to tackle epidemic
Nearly every one of the more than two dozen speakers at this week's Opioid Summit in Madison agreed on one thing: If Mississippi is going to get a handle on its growing drug problem, doctors must swiftly curb the number of opioids they prescribe. In 2014, health care providers in Mississippi wrote 3.36 million prescriptions for opioids, which trans
7/16/17 - Opioids under attack: Government now is on the offensive
On Monday, the Food and Drug Administration said it will require drug manufacturers to better educate physicians about the painkillers. On Tuesday, the Justice Department announced a $35 million settlement with Mallinckrodt Pharmaceuticals, a company charged with looking the other way when it had reason to believe some of its opioids were landing o
7/16/17 - Panel calls on FDA to review opioids
It urges the FDA to bolster a public health approach that already has resulted in one painkiller being pulled from the market. Last week, the maker of opioid painkiller Opana ER withdrew its drug at the FDA's request following a 2015 outbreak of HIV and hepatitis C in southern Indiana linked to sharing needles to inject the pills. Aaron Kesselheim
7/16/17 - Researchers making advancement in HIV/AIDS treatment
By the numbersOver one million people are living with HIV in the United States.One in seven Americans living with HIV do not know they are HIV-positive.HIV/AIDS death rates have fallen by 88 percent since mid-1990.Since the first AIDS cases were reported in the United States in 1981, more than 40 medicines for HIV infection have been approved in th
7/16/17 - Underutilization Of Brain Amyloid Scans Drives Cost And Hurts Alzheimer's Disease Care
LONDON, July 16, 2017/ PRNewswire-USNewswire/ Research reported at the Alzheimer's Association International Conference 2017 in London highlighted the clinical value of amyloid- PET scans, which detect the presence of amyloid-beta plaques in the brain- one of the hallmarks of Alzheimer's disease. Studies also revealed an underutilization of...
7/16/17 - WHY DRUGMAKERS AREN'T
a health-care analyst at research firm Washington Analysis LLC. Over the next three years, roughly $60 billion of drug sales for companies including Roche Holding AG, Sanofi, and Eli Lilly& Co. are threatened by potential rivals, according to a report from the investment firm Sanford C. Bernstein& Co. Among the drugs expected to lose their protecti
7/15/17 - Alder prices $150M offering to fund migraine market scrap [Arab News (Saudi Arabia)]
Alder Biopharmaceuticals has priced a $150 million follow-on offering. The stock sale will set Alder up to forge ahead with development of a migraine drug it thinks can carve out a space in a market fought over by larger rivals such as Amgen and Eli Lilly. Bothell, Washington- based Alder plans to use the money to finish a pivotal trial program for
7/15/17 - Allena claims orphan status for `devastating` rare disease therapy [Arab Finance (Egypt)]
Allena Pharma has been granted orphan status by the FDA for a drug to treat primary hyperoxaluria, a rare disease that causes kidney and bladder stones and can lead to kidney failure and death. The drugcalled ALLN-177is a non-absorbed formulation of an enzyme designed to break down a substance called oxalate in the gastrointestinal tract.
7/15/17 - AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera from 3 abstracts presented at the...
AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera from 3 abstracts presented at the 22nd Congress of the European Hematology Association EHA in Madrid. By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week AOP Orphan Pharmaceuticals AG and PharmaEssentia Corporation..
7/15/17 - AVEO Oncology Announces Positive CHMP Opinion for Tivozanib as a Treatment of Advanced Renal Cell Carcinoma
By a News Reporter-Staff News Editor at Marketing Weekly News AVEO Oncology announced that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has recommended FOTIVDA? for approval as a treatment for patients with advanced renal cell carcinoma. If approved by the EC, marketing authoriza
7/15/17 - But this money-or-your-life extortion racket isn't the root of the case against him
Louisiana is plagued by obesity, opioid addiction and other health crises. Hepatitis C destroys the liver, but the drugs to treat it cost $85,000 for a 12- week regimen. But Louisiana's health secretary has landed on a novel approach that other states are watching.
7/15/17 - Data from Oulu University Hospital Advance Knowledge in Anemia (The Effect of Preoperative Anemia on the Outcome After Coronary Surgery)
For more information on this research see: The Effect of Preoperative Anemia on the Outcome After Coronary Surgery. World Journal of Surgery, 2017; 41: 1910-1918. World Journal of Surgery can be contacted at: Springer, 233 Spring St, New York, NY 10013, USA. Our news journalists report that additional information may be obtained by contacting F. Bi
7/15/17 - Genetically Enhanced, Cord-Blood Derived Immune Cells Strike B-Cell Cancers
The University of Texas MD Anderson Cancer Center issued the following news release:. Immune cells with a general knack for recognizing and killing many types of infected or abnormal cells also can be engineered to hunt down cells with specific targets on them to treat cancer, researchers at The University of Texas MD Anderson Cancer Center report
7/15/17 - Global Cardiovascular Peptides Market Share by Industry Research 2016 - 2024
Transparency Market Research Report Added "Cardiovascular Peptides Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016- 2024" Albany, NY 07/14/2017 Global Cardiovascular Peptides Market: OverviewPeptide therapeutics has been around for decades, but recently there has been an incease in interest of the pharmaceutica
7/15/17 - Jamaica Cancer Drug Aims For Yearly US$250m Haul [T-break Tech (Middle East)]
Scientist and businessman Dr Henry Lowe is predicting annual sales of US $250 million, the equivalent of around $32 billion, from Cresorol, an anti-cancer drug made from marijuana. The product, which targets acute myeloid leukemia has been designated an `orphan drug` by the US Food and Drug Administration, the FDA, but the American regulator also n
7/15/17 - JAMAICA-MARIJUANA-Government will ensure standards are met in marijuana industry
Prime Minister Andrew Holness, says the Government will be exercising caution in how cannabis is leveraged in the development of Jamaica's nutraceutical industry. The Prime Minister was speaking at a ceremony to announce the United States Food and Drug Administration's award of Orphan Drug Status for' Chrysoeriol', which has been developed by Flavo
7/15/17 - New class of breast cancer drugs deemed well-tolerated [Sport360]
The U.S. Food and Drug Administration recently approved the first CDK inhibitor palbociclib or Ibrance, in February 2015 and ribociclib or Kisqali in March 2017. "CDK inhibitors have changed the landscape of management of HR+ breast cancer," Aditya Bardia, a specialist in breast cancer at the Massachusetts General Hospital Cancer Center in Boston,
7/15/17 - Novel leukemia treatment could be 1st U.S. gene therapy
A treatment for a common childhood blood cancer could become the first gene therapy available in the U.S.. A Food and Drug Administration advisory panel voted 10-0 on Wednesday in favor of the leukemia treatment developed by the University of Pennsylvania and Novartis Corp. The FDA usually follows recommendations from its expert panels, but isn't o
7/15/17 - OBI Pharma signs agreement with Abzena for ADC linker technology [Sport360]
UK- headquartered drug development technology and services provider Abzena plc, has signed a licensing agreement and a master services and clinical supply agreement with Taipei, Taiwan biotech OBI Pharma for its novel site-specific ThioBridge antibody drug conjugate linker technology to develop OBIs proprietary ADC, OBI-999 and a series of further
7/15/17 - OPINION: How to think about the Senate's (latest) health care bill [Detroit Free Press]
July 15 Why should anyone care what I think about the Senate's latest proposal to repeal and replace Obamacare? And even if you're not as cynical as he is, it's fair to assume that my take on the Senate bill is shaped largely by my own values. So today, in lieu of passing judgement on a bill that is likely to undergo even further changes before i
7/15/17 - Pfizer Xeljanz Label Expansion Application Accepted by FDA [Sudan Tribune]
Pfizer Inc. `s PFE supplemental new drug application for Xeljanz has been accepted for review by the FDA. Xeljanz, a JAK inhibitor, is presently approved in the U.S. as a second-line treatment for moderate-to-severely active rheumatoid arthritis in patients who have had an inadequate response to or cannot tolerate methotrexate. A response from the
7/15/17 - Rapidly Increasing Cost of Branded Drugs and Aging Populations Drives the Global Authorized Generics Market
Transparency Market Research Report Added "Authorized Generics Market- Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016- 2024" Albany, NY 07/14/2017 A generic drug is a duplicate copy of original branded drug, which has same dosage form, active pharma ingredients, strength, route of administration, and also same intend
7/15/17 - Roche`s hold on Avastin, Herceptin sales loosens as FDA panel backs Amgen and Mylan biosims [Arab News (Saudi Arabia)]
Roche took a blockbuster double hit Thursday as the FDAs Oncologic Drugs Advisory Committee recommended an Amgen biosimilar to Avastin in the morning, and then a Mylan biosim to Herceptin in the afternoon. The committee voted 17-0 to recommend FDA approval for Amgens ABP 215, an Avastin biosimilar, in each of the approved indications for the refere
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415